Aiosyn’s NephroPath quantitative image analysis featured in Physiogenex’s research posters at ASN Kidney Week

Aiosyn’s NephroPath platform* was highlighted at ASN Kidney Week 2024 in San Diego, as our partner Physiogenex presented research that leveraged our AI-powered image analysis technology to assess drug efficacy in preclinical kidney models.

Physiogenex has been developing innovative CRO preclinical services and animal models to evaluate the efficacy of drugs targeting metabolic diseases, including kidney diseases. Our collaboration enabled precise, quantitative analysis of tubuli impairment, glomerulosclerosis, and mesangial expansion (Figure 1) —key indicators in kidney pathology. Through NephroPath, Physiogenex showcased the role of AI-powered pathology tools in advancing drug discovery and development, capturing the attention of ASN Kidney Week attendees.

Physiogenex’s featured posters:

• Poster SA-PO732: Quantitative image analysis uncovers the efficacy of the selective endothelin A receptor antagonist atrasentan in a rat model of IgA Nephropathy.

• Poster SA-PO254: Quantitative image analysis reveals the benefits of dapagliflozin on glomerulosclerosis, podocyte effacement, and kidney fibrosis in the SDT fatty rat model of diabetic nephropathy.

This collaboration with Physiogenex exemplifies Aiosyn’s commitment to supporting preclinical research with robust, data-driven kidney image analysis solutions that help accelerate breakthroughs in renal disease treatment.

Figure 1. The NephroPath platform uncovers how atrasentan reduces the marked mesangial expansion in rats with IgA nephropathy. AI-powered assessment of glomeruli with mesangial expansion: count (A), % of total glomeruli (B), representative pictures illustrating both original H&E staining and image analysis layers at different stages of mesangial expansion (C). Blue zones indicate normal glomerulus structure. Green zones indicate mesangial expansion. *p<0.05, **p<0.01, ***p<0.001 vs. vehicle. Figure retrieved from Poster SA-PO732: https://www.physiogenex.com/wp-content/uploads/2024/10/poster-iga-glomerulonephritis-rat-model_asn_kidney-week-2024.pdf

*Note: Aiosyn’s NephroPath platform is currently designated for Research Use Only. 

About Aiosyn 

Based in the Netherlands, Aiosyn develops precision pathology software for kidney disease and breast cancer, integrating its solutions into standard pathology workflows. Aiosyn has been built upon more than 20 years of research experience in the field of pathology and is rooted in pathology practice. 

About Physiogenex

Physiogenex is one of the leading CRO companies specializing in preclinical drug efficacy studies for metabolic diseases (obesity, type 2 diabetes and related comorbidities). It works with over 100 biopharmaceutical companies all around the world. Physiogenex has been on the market for more than 20 years, driving the performance of innovative biotechs and some of the biggest pharmaceutical companies in the world. Its areas of interest include, but are not limited to, fibrosis and diabetic nephropathy.